It is not difficult to see from the results of these clinical trials that in malignant melanoma, the combination of BRAF inhibitors and MEK inhibitors cannot only improve OS and PFS but also delay the recurrence and reduce the incidence of drug‐related adverse reactions, especially the incidence of secondary skin tumors. The gene discussed is BRAF; the disease is melanoma.